• Novel efti combination achieves 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma
• Over 3-fold greater than historical results from standard-of-care radiotherapy alone
• Data presented at ESMO 2025 Congress

Immutep Limited announced positive data from the EFTISARC-NEO Phase II trial, which were presented at the 2025 European Society of Medical Oncology (ESMO) Congress. The investigator-initiated study evaluating eftilagimod alfa (efti) with radiotherapy plus pembrolizumab in the neoadjuvant setting for resectable soft tissue sarcoma (STS) met the primary endpoint, achieving a median 51.5% tumour hyalinization/fibrosis in the evaluable patient population (N=38), which is over three times greater than the 15% historical results from standard-of-care radiotherapy alone. These promising results were achieved across multiple STS subtypes, and the study also demonstrated a very good safety profile for the therapy. The investigators believe these findings could help pave the way for a new therapeutic option in this challenging indication with significant unmet medical need. Immutep's CEO, Marc Voigt, expressed gratitude to the study investigators and patients for their participation in this important trial.

The positive results from the EFTISARC-NEO trial evaluating efti in soft tissue sarcoma further demonstrate the potential of Immutep's lead product candidate to provide meaningful clinical benefit across a variety of solid tumour indications. Immutep remains committed to advancing efti through late-stage development and towards potential regulatory approvals.